Literature DB >> 15840415

Sex differences in concomitant medication with benzodiazepines or antidepressants in first-break schizophrenic patients treated with antipsychotic medication.

Claudia A W Rijcken1, H Knegtering, Richard Bruggeman, Hilde Tobi, Lolkje T W de Jong-van den Berg.   

Abstract

During a first episode of psychosis, treatment with antipsychotic drugs can improve both positive and negative symptoms. If sufficient amelioration does not occur, adding psychotropic comedication may result in a favorable outcome. To establish sex differences in psychotropic comedication use, we conducted an exploratory retrospective study among first-break patients diagnosed with schizophrenia or schizophreniform disorder. Concerning patient characteristics, no difference in age or antipsychotic drug use was established. At admission, men significantly more often had comorbid substance abuse. Analysis showed that significantly more women than men received benzodiazepines after the onset of psychosis (OR 1.92, 95% CI 1.13-1.27). No sex difference was found in antidepressant comedication (OR 1.22, 95% CI 0.48-3.11). We established a definite sex difference in concomitant benzodiazepine use in first-break patients with schizophrenia. Since women have a better prognosis, we suggest further research to evaluate the efficacy and safety of early benzodiazepine use in the course of schizophrenia. Furthermore, we recommend investigating the possible correlation between benzodiazepine use and substance abuse as a way of treating premorbid symptoms of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15840415     DOI: 10.1016/j.psychres.2003.06.005

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  1 in total

1.  What are the Predictive Factors for the Treatment Outcomes in Multi Drug Poisoning Including Antidepressants/Antipsychotic Drugs?

Authors:  Mohadeseh Ghasemi; Ahmad Yaraghi; Ziba Farajzadegan; Ali Mohammad Sabzghabaee; Nastaran Eizadi-Mood
Journal:  Adv Biomed Res       Date:  2018-10-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.